Bei Akademie registrieren
Faeth Therapeutics stock, PIKTOR

Faeth Therapeutics stock: PIKTOR data due by year-end

Published on 11/05/2026 at 03:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Faeth Therapeutics stock has a year-end clinical catalyst as PIKTOR data are expected in endometrial cancer. Cash reserves reached 174.8 million US dollars.

Faeth sets near-term oncology catalysts

  • Faeth expects topline Phase-2 data for PIKTOR in advanced endometrial cancer by the end of 2026.
  • The FDA granted Fast Track designation to PIKTOR with paclitaxel for a biomarker-selected patient group.
  • Cash, cash equivalents and marketable securities totaled 174.8 million US dollars at September 30.
Faeth Therapeutics stock, PIKTOR, oncology biotech, clinical trials, third-quarter results, Illustration mit AI erstellt.
Faeth Therapeutics stock, PIKTOR, oncology biotech, clinical trials, third-quarter results, Illustration mit AI erstellt.

Faeth Therapeutics reported third-quarter results on November 3, 2026, and set a near-term clinical milestone for investors: topline data from the Phase 2 PIK-201 trial of PIKTOR in advanced endometrial cancer are expected by year-end. The update was published by Business Wire.

Clinical milestones shape the outlook

PIKTOR is an investigational oral combination of serabelisib, a PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor. Faeth is testing the treatment in a Phase 2 study for second-line advanced endometrial cancer and in a Phase 1b/2 study for HR-positive, HER2-negative advanced breast cancer.

The company said the first patient in the breast-cancer study was dosed in April 2026, with interim data expected in 2027. Faeth also reported that the FDA granted Fast Track designation to PIKTOR combined with paclitaxel for patients with advanced or recurrent endometrial cancer whose tumors carry a PI3K/AKT/mTOR pathway alteration and who previously received platinum-based chemotherapy and an immune checkpoint inhibitor.

Cash supports development spending

Cash, cash equivalents and marketable securities stood at 174.8 million US dollars on September 30, compared with 21.2 million US dollars at December 31, 2025. Research and development expenses rose to 11.7 million US dollars in the quarter from 2.5 million US dollars a year earlier, while general and administrative expenses increased to 10.4 million US dollars from 2.3 million US dollars.

Faeth posted a net loss of 20.4 million US dollars, or 0.79 US dollars per basic and diluted share, compared with a loss of 4.6 million US dollars, or 3.62 US dollars per share, in the prior-year quarter. The wider operating cost base reflects the development of PIKTOR and other programs, as well as higher personnel and administrative expenses.

Faeth Therapeutics at a glance

  • Company: Faeth Therapeutics, Inc.
  • Ticker: FTH
  • Exchange: Nasdaq
  • Reporting period: Quarter ended September 30, 2026
  • Net loss: 20.4 million US dollars
  • Cash, cash equivalents and marketable securities: 174.8 million US dollars at September 30, 2026
Disclaimer...
en | boerse | 70460397 |